Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential WBPDT for Superficial Bladder Cancer
NCT00322699Phase 2Completed
- Sponsor
- North Florida/South Georgia Veterans Health System
- Start
- Feb 2005
- Primary completion
- Apr 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of porfimer sodium in Non-muscle-invasive bladder cancer (NMIBC), sponsored by North Florida/South Georgia Veterans Health System. Primary endpoint: Dose Limiting Toxicity at 18 months. Started Feb 2005; status: completed.
02
Drugs
porfimer sodium
03
Conditions
Non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT00322699.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00322699.